PAYER POLICY CHANGES

Q5173 Insurance Policy Changes

HCPCS Q5173 is referenced in 28 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Blue Cross Blue Shield of Nebraska, and 10 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q5173 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross Blue Shield of North Dakota · Effective Nov 10, 2026High impact
Pharmacy Policies Available Online
Blue Cross Blue Shield of North Dakota has revised its commercial prior authorization medical drug policies for drugs including Avlayah, bendamustine, bevacizumab, denosumab, omalizumab, Pluvicto and Sarclisa, with revisions effective November 10, 2026. Several HCPCS changes are effective October 1, 2026, including HCPCS codes J1757, J9066 and Q5173, and J3590 is discontinued for Avlayah, Ponlimsi and denosumab-adet on that date. The updates also add the number of days allowed to the Length of Authorization sections, replace specific contraindications in Universal Criteria with general FDA contraindication language, and add ICD-10 codes including C83.36 and C50.A0 through C50.A2.
Blue Cross Blue Shield of Nebraska · Effective Dec 15, 2026High impact
Medical/Pharmacy Policy Updates Effective 12/15/2026
Blue Cross and Blue Shield of Nebraska (BCBSNE) is implementing a new medical policy (MPC X.242 OptimizeRX) effective 12/15/2026 that establishes step therapy requirements for multiple biologic medications. Preauthorization is now required for all nonpreferred products, and patients must demonstrate contraindication, intolerance, or failure to a preferred product before nonpreferred alternatives will be considered. This applies to both new and established patients across denosumab, infliximab, rituximab, tocilizumab, and trastuzumab drug classes.
Blue Cross Blue Shield of Nebraska · Effective Dec 15, 2026High impact
Medical/Pharmacy Policy Updates Effective 12/15/2026
Blue Cross and Blue Shield of Nebraska (BCBSNE) has implemented a new step therapy requirement for six biologic drug classes effective 12/15/2026. Patients on non-preferred products (biosimilars and brand-name biologics) now require prior authorization and documented evidence of contraindication, intolerance, or failure to a preferred product before coverage. This affects denosumab, infliximab, rituximab, tocilizumab, and trastuzumab products across all patient populations.
UnitedHealthcare · Effective Jan 1, 2027High impact
Denosumab
Effective 2027-01-01, UnitedHealthcare Community Plan of Tennessee revised its Medicaid medical benefit policy for denosumab. Jubereq and Osvyrti are now preferred products covered under the Diagnosis-Specific Criteria, while Boncresa, Oziltus, and Ponlimsi are non-preferred products covered only if the Preferred Product Criteria and Diagnosis-Specific Criteria are both met. The policy also adds a very-high-fracture-risk criterion for initial osteoporosis therapy and adds HCPCS codes Q5166, Q5171, and Q5173.
UnitedHealthcare · Effective Jan 1, 2027High impact
Denosumab
Effective 2027-01-01, UnitedHealthcare Community Plan of New Mexico Medicaid expanded its denosumab policy: Jubereq and Osvyrti are preferred products covered under the Diagnosis-Specific Criteria, while Boncresa, Oziltus, and Ponlimsi are non-preferred and covered only when the Preferred Product Criteria and Diagnosis-Specific Criteria are both met. The postmenopausal osteoporosis criteria add a very-high-fracture-risk pathway for initial therapy, and HCPCS codes Q5166, Q5171, and Q5173 were added.
UnitedHealthcare · Effective Jan 1, 2027High impact
Denosumab
UnitedHealthcare Community Plan of Kentucky's Medicaid medical policy for denosumab was revised effective 2027-01-01, updating the list of covered denosumab products by adding Boncresa, Jubereq, Osvyrti, Oziltus, and Ponlimsi, with Jubereq and Osvyrti designated preferred and Boncresa, Oziltus, and Ponlimsi designated non-preferred. Coverage for postmenopausal osteoporosis treatment was revised to add an initial-therapy criterion for very high fracture risk (a fracture in the past 12 months or a fracture while on approved osteoporosis therapy), and HCPCS codes Q5166, Q5171, and Q5173 were added. Billing staff should update product and code references and review the new very-high-risk documentation requirements before submitting denosumab claims for these members.
UnitedHealthcare · Effective Jan 1, 2027High impact
Denosumab
Effective 2027-01-01, UnitedHealthcare Community Plan (Medicaid, national) revised its denosumab medical benefit drug policy: five new biosimilars were added (Boncresa, Jubereq, Osvyrti, Oziltus, Ponlimsi), Jubereq and Osvyrti are designated preferred products, Boncresa, Oziltus and Ponlimsi are non-preferred, and HCPCS Q5166, Q5171 and Q5173 were added. The osteoporosis coverage criteria were expanded to add a very-high-fracture-risk initial therapy requirement.
Highmark · Effective Jan 1, 2027High impact
Medical Injectable Drug Program Changes in the New Year
Effective January 1, 2027, Highmark is adding 13 new drugs to its Medical Injectable Drug Program and adjusting reimbursement rates to align with average selling price (ASP) or average wholesale price (AWP) for drugs without an ASP. Billing teams must update their systems to recognize the new HCPCS codes and apply the corrected reimbursement methodology for these injectable medications.
Highmark · Effective Jan 1, 2027High impact
Medical Injectable Drug Program Changes in the New Year
Effective January 1, 2027, Highmark is adding 13 new drugs to its Medical Injectable Drug Program and adjusting reimbursement rates to align with average selling price (ASP) or average wholesale price (AWP) for drugs lacking an ASP. These drugs receive HCPCS codes and remain in the program once coded. Billing teams must update their systems to recognize these new HCPCS codes and apply the correct reimbursement methodology.
Blue Cross & Blue Shield of Mississippi · Effective Jan 1, 2027High impact
State and School Employees' Health Insurance Plan - Biosimilar Medications
Remicade, infliximab, Neulasta, Neulasta Onpro, Kanjinti, and Selarsdi will no longer be covered effective 01/01/2027, and services related to delivery or administration of a not covered or non-formulary medication are considered not medically necessary. Prolia, Soliris, and Xgeva were set to no longer be covered effective 08/15/2026, and a policy update dated 11/01/2026 added Avsola, Fulphila, Fylnetra, Granix, Ogivri, Ontruzant, Renflexis, Riabni, Starjemza, and Vegzelma as covered products.
Anthem BCBS · Effective Feb 1, 2027High impact
[Ohio] Specialty pharmacy updates — November 2026
Anthem Blue Cross and Blue Shield (Ohio) is implementing multiple specialty pharmacy utilization management updates effective on staggered dates: step therapy requirements for denosumab biosimilars effective November 1, 2026, and prior authorization, quantity limits, site-of-care restrictions, and clinical criteria revisions for 24 specialty medications effective February 1, 2027. Billing teams must update systems to enforce these requirements for affected HCPCS and CPT codes to avoid claim denials.
UnitedHealthcare · Effective Jan 1, 2027Medium impact
Medicare Part B Step Therapy Programs
UnitedHealthcare's October 2026 Medicare Advantage bulletin revises its Medicare Part B step therapy program, which sets preferred and non-preferred drugs for certain oncology, osteoporosis, testosterone and iron-related drugs, effective January 1, 2027. It adds newly listed generic and branded products with HCPCS codes, moves some bone density products between preferred and non-preferred, and updates the list of plans excluded from the policy.
Anthem BCBS · Effective Nov 1, 2026High impact
[New York] Specialty pharmacy updates — November 2026
Anthem is implementing multiple specialty pharmacy review requirements for New York commercial plans, effective on two dates: November 1, 2026 for step therapy updates affecting denosumab biosimilars, and February 1, 2027 for prior authorization, quantity limits, site-of-care, and clinical criteria updates affecting multiple specialty drugs including golimumab, bevacizumab, isatuximab, and denosumab products. Billing teams must update workflows to obtain prior authorization and verify quantity limits before claim submission for affected medications.
Anthem BCBS · Effective Nov 1, 2026High impact
[Virginia] Specialty pharmacy updates — November 2026
Anthem Blue Cross and Blue Shield is implementing multiple specialty pharmacy management updates for Virginia, effective on two dates: step therapy requirements begin November 1, 2026, while prior authorization, quantity limits, site-of-care reviews, and clinical criteria revisions take effect February 1, 2027. Providers must request prior authorization for specified medications and adhere to new quantity limits and step therapy protocols for affected specialty pharmacy codes.
Anthem BCBS · Effective Nov 1, 2026High impact
[Georgia] Specialty pharmacy updates — November 2026
Anthem Blue Cross and Blue Shield (Georgia) is implementing multiple specialty pharmacy management updates effective on two dates: November 1, 2026 for step therapy reviews, and February 1, 2027 for prior authorization, quantity limits, site-of-care reviews, and clinical criteria revisions. Billing teams must update workflows to require prior authorization and apply quantity limits for specified biosimilar and specialty drugs, and verify step therapy requirements for denosumab products before those dates.
Kansas Medicaid (KanCare) · Effective Oct 1, 2026High impact
KMAP BULLETIN: HCPCS Codes Update – October 2026
Effective October 1, 2026, KMAP is adding 34 new HCPCS codes to coverage and discontinuing 12 existing codes. Billing teams must update their systems to recognize the new covered codes and stop billing the discontinued codes to avoid claim denials.
UnitedHealthcare · Effective Oct 1, 2026High impact
Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (UMR)
UnitedHealthcare's UMR medical policy update bulletin for October 2026 says the annual ICD-10 and quarterly CPT/HCPCS code changes took effect October 1, 2026 across its medical and drug policies. The billing team needs to add the new CPT, HCPCS and ICD-10 codes to charge entry, stop using the codes that were removed, and update the revised descriptions. The bulletin lists the code changes but does not state any coverage decisions beyond the policies it updates, so the practice should check each updated policy before billing the new codes.
UnitedHealthcare · Effective Oct 1, 2026High impact
Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Surest)
UnitedHealthcare's Surest medical policy update bulletin for October 2026 says the annual ICD-10 and quarterly CPT/HCPCS code changes took effect October 1, 2026 across its medical and drug policies. The billing team needs to add the new CPT, HCPCS and ICD-10 codes to charge entry, stop using the codes that were removed, and update the revised descriptions. The bulletin lists the code changes but does not state any coverage decisions beyond the policies it updates, so the practice should check each updated policy before billing the new codes.
UnitedHealthcare · Effective Oct 1, 2026High impact
Denosumab
UnitedHealthcare revised its denosumab coverage policy effective October 1, 2026, consolidating multiple biosimilar products into preferred and non-preferred tiers. Bildyos, Enoby, Prolia, and Stoboclo are now preferred products requiring diagnosis-specific criteria for coverage. Bosaya, Conexxence, Jubbonti, and Ospomyv are typically excluded but may be covered if members fail preferred products or have documented intolerances. Three new oncology-indication products (Boncresa, Osvyrti, Ponlimsi) are subject to a Review at Launch program with potential eligibility restrictions.
Texas Medicaid · Effective Oct 1, 2026High impact
Third Quarter 2026 HCPCS Updates for Texas Medicaid
Texas Medicaid's third quarter 2026 HCPCS update made new codes effective for dates of service on or after October 1, 2026, which is already in effect. Several added drug codes will be denied until a rate is implemented and then reprocessed back to October 1, while other added codes are pending a rate hearing, some codes are non-covered, and 18 codes were discontinued after September 30, 2026. Some codes carry prior authorization, age or diagnosis limits, so the billing team needs to update charge entry before claims go out.
Indiana Medicaid (IHCP) · Effective Oct 1, 2026High impact
BT2026163: Coverage and billing information for the October 2026 quarterly HCPCS code update
Indiana Medicaid (IHCP) added new CPT and HCPCS procedure codes in its October 2026 quarterly HCPCS update, effective for dates of service on or after Oct. 1, 2026. Each new code is marked covered or noncovered, and the table shows whether each covered code requires prior authorization and an NDC. Pricing for these codes is pending final CMS fee schedule posting, and a later IHCP publication will announce when pricing is implemented along with additional coverage and billing details.
Premera Blue Cross · Identified Oct 1, 2026High impact
Medical Policy and Coding Updates - October 2026
Premera's October 2026 medical policy update covers new, revised and deleted medical policies, pharmacy policies, and coding changes with effective dates from October 1, 2026 through January 1, 2027. Several policies now require medical necessity review and prior authorization, including Denosumab Products (5.01.658), Miscellaneous Oncology Drugs (5.01.540) and ALK Tyrosine Kinase Inhibitors (5.01.638), and Bioengineered Skin and Soft Tissue Substitutes (7.01.582) and Laboratory Testing Investigational Services (2.04.520) are now considered investigational. Changes dated October 1, 2026 are already effective, and changes dated November 6, 2026 and later are future changes.
Independence Blue Cross · Effective Oct 1, 2026Medium impact
08.00.94x, Denosumab (Prolia®, Xgeva®) and related biosimilars, and Romosozumab-aqqg (Evenity®)
Independence Blue Cross updated policy 08.00.94x effective 10/01/2026 to add new denosumab biosimilar code Q5173 (denosumab-adet/Ponlimsi), reorganize romosozumab-aqqg (Evenity) criteria for high-risk fracture patients, and move systemic mastocytosis indication from Xgeva to Prolia formulation. Billing teams must update coding systems to recognize the newly covered biosimilar and ensure claims route to the correct preferred/non-preferred product tier.
Independence Blue Cross · Effective Oct 1, 2026Medium impact
MA08.052r, Denosumab (Prolia®, Xgeva®) and related biosimilars, and Romosozumab-aqqg (Evenity®)
Independence Blue Cross Medicare Advantage updated policy MA08.052r effective 10/01/2026 to add coverage for romosozumab-aqqg (Evenity) in individuals with severely deteriorated condition/very high risk for fracture, relocate systemic mastocytosis indication from Xgeva to Prolia, and add HCPCS code Q5173 for denosumab-adet (Ponlimsi) biosimilar. Billing teams must implement the new code and verify coverage criteria align with the updated indications.
UnitedHealthcare · Effective Oct 1, 2026Medium impact
Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Exchange)
Effective October 1, 2026, UnitedHealthcare updated several Individual Exchange medical policies to match the annual ICD-10 and quarterly CPT/HCPCS code changes. The bulletin adds many new codes across areas such as cardiology, pregnancy, hematology, genetic testing and pain or rehabilitation, and it removes a smaller set of older codes.
UnitedHealthcare · Effective Oct 1, 2026Medium impact
Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Commercial)
UnitedHealthcare's Commercial medical and drug policies were updated effective October 1, 2026 to match the annual ICD-10 and quarterly CPT/HCPCS code changes. Codes were added, revised or removed across topics including genetic testing, molecular oncology, cell therapy, pregnancy preventive care, sudden cardiac arrest risk and Category III codes, so the billing team needs to update its code lists and charge entry tables to match.
Texas Medicaid · Effective Oct 1, 2026Medium impact
Third Quarter 2026 HCPCS Updates for the CSHCN Services Program
Texas Medicaid's CSHCN Services Program posted its third quarter 2026 HCPCS update, effective for dates of service on or after October 1, 2026. It adds codes as benefits pending a rate hearing, adds noncovered codes, ends reimbursement for discontinued codes after September 30, 2026, and revises several descriptions. Because October 1, 2026 has passed, these rules are already in effect.
Blue Cross Blue Shield of Rhode Island · Effective Oct 1, 2026Medium impact
Additional HCPCS Level II Code Changes and Modifier Changes
Blue Cross and Blue Shield of Rhode Island published its review of October 2026 HCPCS and modifier changes on September 14, 2026, effective October 1, 2026. It sets coverage and payment rules for about 45 HCPCS codes: some are now covered and separately paid, some need medical review or preauthorization, some are not covered for Medicare Advantage, and some should not be billed separately by institutional providers. The rules may change for Medicare Advantage and Commercial products, so the billing team should recheck the BCBS RI provider update page.

Watch Q5173

Get one email when a payer policy names Q5173, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

FREQUENTLY ASKED QUESTIONS

Does Aetna require prior authorization for Q5173?

Aetna lists Q5173 on Participating provider precertification list for Aetna for commercial plans (list dated November 1, 2026). Verify with the payer before scheduling.

Does Anthem BCBS require prior authorization for Q5173?

Anthem BCBS lists Q5173 on Anthem Local PPO Precertification/Prior Authorization List (California | Anthem Blue Cross | Commercial) for commercial plans (list dated November 1, 2026). Verify with the payer before scheduling.

Does BCBS Arizona require prior authorization for Q5173?

BCBS Arizona lists Q5173 on AZ Blue Standard Prior Authorization Requirements Code List (Updated 10/01/2026) for commercial plans (list dated October 1, 2026). Verify with the payer before scheduling.

Does BCBS Michigan require prior authorization for Q5173?

BCBS Michigan lists Q5173 on BCBSM medical drug and step therapy prior authorization list for Medicare Plus Blue and BCN Advantage for medicare advantage plans (list dated October 2, 2026). Verify with the payer before scheduling.

Does Capital Blue Cross require prior authorization for Q5173?

Capital Blue Cross lists Q5173 on Capital Blue Cross single source preauthorization code list for commercial plans, with conditions. Verify with the payer before scheduling.

What insurance policy changes affect HCPCS Q5173?

There are 28 tracked policy changes affecting HCPCS Q5173, including updates from Blue Cross Blue Shield of North Dakota, Blue Cross Blue Shield of Nebraska, UnitedHealthcare. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS Q5173?

Payers that have issued tracked updates for HCPCS Q5173 include: Blue Cross Blue Shield of North Dakota, Blue Cross Blue Shield of Nebraska, UnitedHealthcare, Highmark, Blue Cross & Blue Shield of Mississippi, Anthem BCBS, Kansas Medicaid (KanCare), Texas Medicaid, Indiana Medicaid (IHCP), Premera Blue Cross, Independence Blue Cross, Blue Cross Blue Shield of Rhode Island.

How do I get notified when HCPCS Q5173 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS Q5173. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for HCPCS Q5173?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

See every payer rule for Q5173

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for Q5173 in one place.

See every payer rule

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pharmacy Policies Available Online

Medical/Pharmacy Policy Updates Effective 12/15/2026

Medical/Pharmacy Policy Updates Effective 12/15/2026

Denosumab

Denosumab

Denosumab

Denosumab

Medical Injectable Drug Program Changes in the New Year

Medical Injectable Drug Program Changes in the New Year

State and School Employees' Health Insurance Plan - Biosimilar Medications

[Ohio] Specialty pharmacy updates — November 2026

Medicare Part B Step Therapy Programs

[New York] Specialty pharmacy updates — November 2026

[Virginia] Specialty pharmacy updates — November 2026

[Georgia] Specialty pharmacy updates — November 2026

KMAP BULLETIN: HCPCS Codes Update – October 2026

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (UMR)

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Surest)

Denosumab

Third Quarter 2026 HCPCS Updates for Texas Medicaid

BT2026163: Coverage and billing information for the October 2026 quarterly HCPCS code update

Medical Policy and Coding Updates - October 2026

08.00.94x, Denosumab (Prolia®, Xgeva®) and related biosimilars, and Romosozumab-aqqg (Evenity®)

MA08.052r, Denosumab (Prolia®, Xgeva®) and related biosimilars, and Romosozumab-aqqg (Evenity®)

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Exchange)

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Commercial)

Third Quarter 2026 HCPCS Updates for the CSHCN Services Program

Additional HCPCS Level II Code Changes and Modifier Changes

Prior authorization required

Prior authorization required

Prior authorization required

Does Aetna require prior authorization for Q5173?

Does Anthem BCBS require prior authorization for Q5173?

Does BCBS Arizona require prior authorization for Q5173?

Does BCBS Michigan require prior authorization for Q5173?

Does Capital Blue Cross require prior authorization for Q5173?

What insurance policy changes affect HCPCS Q5173?

Which payers have updated policy for HCPCS Q5173?

How do I get notified when HCPCS Q5173 policy changes?

Why do payers change policies for HCPCS Q5173?